“…Although inhibition of hormone receptors, DNA damage repair, and immunomodulatory signaling represent the majority of the approaches to radiosensitization currently being studied in the clinic (Table 1), there are a number of other emerging preclinical radiosensitization strategies ( Abbreviations: DNAPK, DNA-dependent protein kinase; dsDNA, double-strand DNA; EGFR, epidermal growth factor receptor; ER, estrogen receptor; ERK, extracellular regulated kinase; HER2, human epidermal growth factor receptor 2; HR, homologous recombination; mTOR, mammalian target of rapamycin; TNBC, triple-negative breast cancer, VEGF, vascular endothelial growth factor. autophagy in, [149][150][151][152][153][154][155][156] or metabolic changes 157,158 usually thought to be minor contributing pathways to breast cancer radiosensitization, a number of these approaches likely have mixed mechanisms that lead to broad suppression of the DNA damage response, cell-cycle progression, or decreased hypoxia and HIF1a-related signaling. 127,[159][160][161][162][163][164][165][166][167] On-target and off-target effects of compounds designed to affect proliferation or cell-cell communication, such as the suppression of notch signaling 168 through gamma secretase inhibition 169 (Clinical-Trials.gov identifier: NCT01217411), can also be valuable approaches in the radiosensitization of breast cancer.…”